Company intelligence / Profile preview
NuSirt Biopharma
Nashville, Tennessee, United Statesnusirt.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
NuSirt’s clinical studies have shown that its patented combinations can improve outcomes in chronic metabolic diseases. The lead program has completed a Phase 2A trial for type 2 diabetes, while another program targeting NAFLD/NASH is at the Phase II stage. Preclinical data suggest potential to reverse NAFLD, reduce symptoms, and prevent NASH onset. The approach may also lower required doses of established drugs, potentially improving patient compliance.
- Therapeutic areas
- GastroenterologyEndocrinology
- Modalities
- Small moleculesAmino acid combinations (notably leucine with existing drugs)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on NuSirt Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NuSirt Biopharma.